Section Arrow
ARGX.NASDAQ
- argenx SE
Quotes are at least 15-min delayed:2024/05/16 02:28 EDT
Last
 376.96
+20.95 (+5.88%)
Day High 
380.75 
Prev. Close
356.01 
1-M High
400.61 
Volume 
344.66K 
Bid
376.47
Ask
384.83
Day Low
359.41 
Open
359.41 
1-M Low
352.77 
Market Cap 
21.16B 
Currency USD 
P/E -- 
%Yield
10-SMA 381.63 
20-SMA 375.61 
50-SMA 381.27 
52-W High 550.76 
52-W Low 327.725 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.68/2.98
Enterprise Value
21.17B
Balance Sheet
Book Value Per Share
68.95
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
36.42M
Operating Revenue Per Share
16.72
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed:2024/05/16 02:28 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.